OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board
-
Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
-
Avitide, Inc., Raises Series E Financing from Sands Capital Ventures with Broad Participation from Early Investors
-
Form SC 13G CTI BIOPHARMA CORP Filed by: ORBIMED ADVISORS LLC
-
Inspire Medical Systems Announces FDA Approval of Inspire 3028 Neurostimulator for the Treatment of Obstructive Sleep Apnea
-
OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori®) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer
-
OrbiMed Advisors Raises Stake in XTENT, Inc. (XTNT) to 9.9%
-
Form SC 13D Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
TP Therapeutics Closes $45M Series C Financing
-
Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
-
Xtant Medical Announces OrbiMed Financing and Engagement of Aurora Management Partners
-
Form SC 13D Verona Pharma plc Filed by: ORBIMED ADVISORS LLC
-
Nivalis Therapeutics Reports First Quarter 2017 Financial Results
-
Form SC 13D/A SteadyMed Ltd. Filed by: ORBIMED ADVISORS LLC
-
Form 4 SteadyMed Ltd. For: Apr 25 Filed by: ORBIMED ADVISORS LLC
-
Avedro Announces $42 Million in Funding to Support Commercial Expansion and Pipeline Development
-
DiaMedica Announces Dr. Nancy Chang to its Strategic Advisory Board
-
Nivalis Therapeutics (NVLS) to Merge with Alpine Immune Sciences in All-Stock Deal
-
Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc. Agree to Combine
-
Unilife Corp. (UNIS) Files Chapter 11 Bankruptcy in Delaware
-
Unilife Files for Chapter 11 Protection
-
Unilife Corp. (UNIS) Sinks After Warning About Dire Financial Condition, Executing WARN Notice
-
Form 4 Adaptimmune Therapeutics For: Mar 27 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Aerpio Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A ViewRay, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 GLAUKOS Corp For: Mar 03 Filed by: ORBIMED ADVISORS LLC
-
Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update
-
Form SC 13D/A Affimed N.V. Filed by: ORBIMED ADVISORS LLC
-
PMV Pharma Secures $74 Million in Series B Financing for Cancer Drugs Targeting p53
-
Form 4 Aeglea BioTherapeutics, For: Feb 16 Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
-
venBio Takes Steps to Protect Immunomedics (IMMU) Stockholders Following Its Partnership with Seattle Genetics (SGEN)
-
venBio Takes Steps to Protect Rights of Immunomedics Stockholders
-
Form SC 13G/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A XENOPORT INC Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Sientra, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A SYNERGY PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G NEWLINK GENETICS CORP Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Lion Biotechnologies, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G INOTEK PHARMACEUTICALS Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A IMMUNOMEDICS INC Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A IMMUNOGEN INC Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A GLAUKOS Corp Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A FLUIDIGM CORP Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Cellectis S.A. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Wright Medical Group Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A ProQR Therapeutics N.V. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A MAGELLAN HEALTH INC Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Ophthotech Corp. Filed by: ORBIMED ADVISORS LLC

